18th Aug 2006 17:17
18 August 2006Shire plc (the "Company")The Company announces that on 17 August 2006 the following Persons DischargingManagerial Responsibility ("PDMRs") were granted awards under the Shire plcPortfolio Share Plan (the "Plan").Awards of Stock Settled Appreciation Rights ("SARs") under Part A of the PlanName of PDMR Type of Security No of Ordinary Exercise Shares or ADRs price Matthew Emmens (Executive American Depositary 126,831 $49.36 Director)* Receipt ("ADR") Angus Russell (Executive Ordinary Share 128,542 ‚£8.645 Director)* Michael Cola ADR 15,000 $49.36 David Pendergast ADR 14,000 $49.36 Tatjana May Ordinary Share 34,000 ‚£8.645 Barbara Deptula ADR 13,334 $49.36 Eliseo Salinas ADR 10,667 $49.36 Joseph Rus ADR 11,667 $49.36 John Lee ADR 8,667 $49.36 Anita Graham ADR 8,667 $49.36 *Awards to Executive Directors are subject to performance targetsSARs will normally vest after three years. subject to any performance targets.Once vested, SARs will be capable of exercise for a period of two years. Noconsideration was paid for the grant of the SARs.Performance Share Awards ("PSP Awards") under Part B of the PlanName of PDMR Type of Security No of Ordinary Market Shares or ADRs value Matthew Emmens (Executive American Depositary 92,671 $49.36 Director)* Receipt ("ADR") Angus Russell (Executive Ordinary Share 96,406 ‚£8.645 Director)* Michael Cola ADR 14,000 $49.36 David Pendergast ADR 13,334 $49.36 Tatjana May Ordinary Share 34,000 ‚£8.645 Barbara Deptula ADR 13,334 $49.36 Eliseo Salinas ADR 10,667 $49.36 Joseph Rus ADR 11,334 $49.36 John Lee ADR 8,667 $49.36 Anita Graham ADR 11,334 $49.36 *Awards to Executive Directors are subject to performance targetsThe PSP awards will normally vest after three years, subject to any performancetargets. Once vested, sufficient ordinary shares or ADRs will be transferred orallotted to the participant within 30 days. No consideration was paid for thegrant of PSP awards.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on attention deficit and hyperactivity disorder (ADHD),human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. Thestructure is sufficiently flexible to allow Shire to target new therapeuticareas to the extent opportunities arise through acquisitions. Shire believesthat a carefully selected portfolio of products with a strategically alignedand relatively small-scale sales force will deliver strong results.Shire's focused strategy is to develop and market products for specialtyphysicians. Shire's in-licensing, merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protection eitherin the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDSHIRE PLCRelated Shares:
Shire